EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis and fibrosis in high‐risk population

Paula Iruzubieta iD, Rebeca Mayo, Itziar Mincholé iD, Ibon Martínez-Arranz, María Teresa Arias-Loste, Luis Ibañez-Samaniego, Javier Ampuero, Javier Abad, Rosa Martín-Mateos, Ana Belén Fernández-Laso, Agustín Albillos, Rafael Bañares und 4 weitere

United European Gastroenterology Journal · 2024-09 · 12 (7) · 919-929

DOI: 10.1002/ueg2.12589 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 04.08.2024. Verfasst von Paula Iruzubieta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Clinical and Translational Research in Digestive Diseases, Val…. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Liver Cirrhosis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Type 2 Diabetes mellitus (T2DM), age, and obesity are risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to assess the performance of non‐invasive tests (NITs) for the diagnosis of metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis in high‐risk subjects.

Methods

Multicentre cross‐sectional study that included 124 biopsy‐proven MASLD in more than 50 years‐old patients with overweight/obesity and T2DM. Vibration‐controlled transient elastography, Fibrosis‐4 index (FIB‐4), Non‐alcoholic fatty liver disease fibrosis score (NFS), OWLiver Panel (OWLiver DM2 + Metabolomics‐Advanced Steatohepatitis Fibrosis Score ‐MASEF) and FibroScan‐AST were performed. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and area under the receiver operating characteristic curve (AUC) were calculated. NITs were assessed individually and in sequential/parallel combinations.

Results

35 (28.2%) patients had early MASH and 66 (53.2%) had MASH with significant fibrosis (at‐risk MASH). The OWLiver Panel correctly classified 86.1% as MASH, showing an accuracy, sensitivity, specificity, PPV, and NPV of 0.77, 0.86, 0.35, 0.85, and 0.36, respectively. Class III obesity, diabetes control, or gender did not impact on the performance of the OWLiver Panel ( p > 0.1). NITs for at‐risk MASH showed an AUC > 0.70 except for NFS. MASEF showed the highest accuracy and NPV for at‐risk MASH (AUC 0.77 [0.68–0.85], NPV 72%) and advanced fibrosis (AUC 0.80 [0.71–0.88], NPV 92%). Combinations of NITs for the identification of at‐risk MASH did not provide any additional benefit over using MASEF alone.

Conclusion

One‐step screening strategy with the OWLiver Panel has high accuracy to detect MASH and at‐risk MASH in high‐risk subjects for MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elasticity Imaging TechniquesLiver CirrhosisDiabetes Mellitus, Type 2HumansFemaleMaleMiddle AgedCross-Sectional StudiesAgedRisk FactorsObesityPredictive Value of TestsNon-alcoholic Fatty Liver DiseaseROC CurveSensitivity and SpecificityLiverBiopsyFatty Liver

Stichwörter der Autor:innen

MASEF scoreMASLDOWLiver panelat‐risk MASHbiopsyfibroscanmetabolic dysfunction‐associated steatotic liver diseasemetabolic syndromenon‐invasive teststype 2 diabetes mellitus

Autor:innen und Institutionen

  • Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Santander, Spain.
  • OWL Metabolomics, Derio, Spain.
  • Department of Gastroenterology and Hepatology, Gregorio Marañón General University Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), CIBERehd, Madrid, Spain.
  • Department of Digestive Diseases, Virgen del Rocío University Hospital, Clinical and Translational Research Group in Liver and Digestive Diseases, Biomedicine Institute of Sevilla, Sevilla, Spain.
  • Gastroenterology Department, Hepatology Unit, Puerta de Hierro University Hospital, IDIPHISA, Madrid, Spain.
  • Department of Gastroenterology and Hepatology, Ramón y Cajal University Hospital, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), CIBERehd, Madrid, Spain.

ORCID-Profile: Paula Iruzubieta, Itziar Mincholé, José Luis Calleja

Förderung

  • Instituto de Salud Carlos III
  • Pfizer

Zitieren

APA

Iruzubieta, P., Mayo, R., Mincholé, I., Martínez-Arranz, I., Arias-Loste, M. T., Ibañez-Samaniego, L., Ampuero, J., Abad, J., Martín-Mateos, R., Fernández-Laso, A. B., Albillos, A., Bañares, R., Calleja, J. L., Romero-Gómez, M., Aller, R., & Crespo, J. (2024). One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis and fibrosis in high‐risk population. United European Gastroenterology Journal, 12(7), 919-929. https://doi.org/10.1002/ueg2.12589

Vancouver

Iruzubieta P, Mayo R, Mincholé I, Martínez-Arranz I, Arias-Loste MT, Ibañez-Samaniego L, et al. One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis and fibrosis in high‐risk population. United European Gastroenterology Journal. 2024;12(7):919-929. doi:10.1002/ueg2.12589

BibTeX
@article{Iruzubieta2024,
  author = {Iruzubieta, Paula and Mayo, Rebeca and Mincholé, Itziar and Martínez-Arranz, Ibon and Arias-Loste, María Teresa and Ibañez-Samaniego, Luis and Ampuero, Javier and Abad, Javier and Martín-Mateos, Rosa and Fernández-Laso, Ana Belén and Albillos, Agustín and Bañares, Rafael and Calleja, José Luis and Romero-Gómez, Manuel and Aller, Rocío and Crespo, Javier},
  title = {One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis and fibrosis in high‐risk population},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  volume = {12},
  number = {7},
  pages = {919--929},
  doi = {10.1002/ueg2.12589}
}
Kostenlos starten →